Myia is a technology company offering an intelligent health monitoring platform that is headquartered in San Francisco, California and was founded in 2017 by Alex Gold, Sam Rawstorne, Simon MacGibbon, and W. Bryan Smith.
The companies health monitoring platform is made to help patients prevent illness, manage their chronic illnesses, and improve their daily quality of life. Myia uses data from the environment, behaviour, physiology, symptoms, outcomes, clinical guidelines, and medical history. The companies platform collects user data from wearable devices capable of monitoring patients with chronic illnesses or are in post-operative condition. The company uses wearable device health and machine learning to measure heart rate, heart rate variability, respiratory rate, blood pressure, and sleep to produce data that can be used to improve health.
On November 30, 2018 Myia completed their seed funding round with $6.75 million in funding from BootstrapLabs (lead investor), Zetta Venture Partners (lead investor), American College of Cardiology (ACC), and The Boston Consulting Group. The companies CEO, Simon MacGibbon, made the following comments regarding the technological and market conditions making Myia possible and what the company plans on using their seed funding for:
We’ve had streams of real-world health data for years, but only now with the advances of machine learning and AI techniques can we start turning this data into trustworthy, actionable clinical insights and scale preventative virtual care in an unprecedented way. Many of these biometric markers of patient health status have been established in academic settings but have not been accessible and translated for practical use. We’re excited to be partnering with leaders in the medical profession to bring real-world insight into the clinic.
Myia raises a $6,750,000 seed round from Boston Consulting Group, American College of Cardiology, BootstrapLabs and Zetta Venture Partners.